A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositis

Recruiting

• Conditions: juvenile dermatomyositis; 10028302; rheumatic muscle disease; 10003816

• Registration Number: NL-OMON50706
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 365

Inclusion Criteria

JDM:
- consenting to participate
- diagnosis of JDM according to Bohan and Peter criteria and/or EULAR/ACR
classification criteria.
- age < 18 years
S4S disease controls:
- consenting to participate
- age < 18 years
- diagnosis of congenital myopathy, muscular dystrophy or mitochondrial
myopathy or other non-inflammatory myopathies or neuromuscular diseases
Adult IIM:
- Consenting to participate
- Definite IIM according to EULAR/ACR classification criteria
- Myositis overlap syndromes
- Age >=18 yrs
Systemic autoimmune diseases:
- Diagnosis of systemic lupus erythematodes (SLE), mixed connective tissue
disease (MCTD), overlap syndromes, scleroderma/morphea, vasculitis, or other
systemic autoimmune disease
Healthy controls:
- Consenting to participate
- Age <18 years

Exclusion Criteria

In all groups: no informed consent
S4S disease controls: chronic inflammatory diseases
Healthy controls: immune-mediated, neurological or metabolic diseases

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>With this study we want to determine the applicability of three proteins as<br /><br>biomarkers to assess disease activity in Juvenile dermatomyositis. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>In addition we want to look into detail in the role of IL-18, CCL2, CCL4,<br /><br>CCL19, CCL27, CXCL10, CXCL13, TNFR1, TNFR2, galectin-9 and other potential<br /><br>biomarkers in the immunopathogenesis of JDM in relation to other systemic<br /><br>autoimmune diseases. </p><br>